Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiretroviral therapy: current drugs.

Literature DB >> 25151562

Antiretroviral therapy: current drugs.

Abstract

The rapid advances in drug discovery and the development of antiretroviral therapy is unprecedented in the history of modern medicine. The administration of chronic combination antiretroviral therapy targeting different stages of the human immunodeficiency virus' replicative life cycle allows for durable and maximal suppression of plasma viremia. This suppression has resulted in dramatic improvement of patient survival. This article reviews the history of antiretroviral drug development and discusses the clinical pharmacology, efficacy, and toxicities of the antiretroviral agents most commonly used in clinical practice to date. Published by Elsevier Inc.

Entities: Chemical Disease Gene Mutation Species

Keywords: Antiretroviral therapy; CCR5 antagonist; Fusion inhibitor; HIV; Integrase strand transfer inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside/nucleotide reverse transcriptase inhibitors; Protease inhibitors

Mesh：

Substances：
Anti-Retroviral Agents

Year: 2014 PMID： 25151562 PMCID： PMC4143801 DOI： 10.1016/j.idc.2014.06.001

Source DB: PubMed Journal: Infect Dis Clin North Am ISSN： 0891-5520 Impact factor: 5.982

39 in total

1. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

Authors: P H Frissen; J de Vries; H M Weigel; K Brinkman
Journal: AIDS Date: 2001-01-26 Impact factor: 4.177

2. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.

Authors: A M Cattelan; M L Calabrò; P Gasperini; S M Aversa; M Zanchetta; F Meneghetti; A De Rossi; L Chieco-Bianchi
Journal: J Natl Cancer Inst Monogr Date: 2001

3. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors: R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal: Proc Natl Acad Sci U S A Date: 1999-12-21 Impact factor: 11.205

4. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Authors: S Hetherington; S McGuirk; G Powell; A Cutrell; O Naderer; B Spreen; S Lafon; G Pearce; H Steel
Journal: Clin Ther Date: 2001-10 Impact factor: 3.393

5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245

6. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245

7. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors: E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal: N Engl J Med Date: 1994-11-03 Impact factor: 91.245

8. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors: M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal: N Engl J Med Date: 1987-07-23 Impact factor: 91.245

9. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

Authors: M M Lederman; E Connick; A Landay; D R Kuritzkes; J Spritzler; M St Clair; B L Kotzin; L Fox; M H Chiozzi; J M Leonard; F Rousseau; M Wade; J D Roe; A Martinez; H Kessler
Journal: J Infect Dis Date: 1998-07 Impact factor: 5.226

10. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Authors: Antonella Castagna; Franco Maggiolo; Giovanni Penco; David Wright; Anthony Mills; Robert Grossberg; Jean-Michel Molina; Julie Chas; Jacques Durant; Santiago Moreno; Manuela Doroana; Mounir Ait-Khaled; Jenny Huang; Sherene Min; Ivy Song; Cindy Vavro; Garrett Nichols; Jane M Yeo
Journal: J Infect Dis Date: 2014-01-19 Impact factor: 5.226

58 in total

1. HIV and HCV Medications in End-Stage Renal Disease.

Authors: Keiko I Greenberg; Mark A Perazella; Mohamed G Atta
Journal: Semin Dial Date: 2015-04-06 Impact factor: 3.455

2. Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.

Authors: William T Gray; Kathleen M Frey; Sarah B Laskey; Andrea C Mislak; Krasimir A Spasov; Won-Gil Lee; Mariela Bollini; Robert F Siliciano; William L Jorgensen; Karen S Anderson
Journal: ACS Med Chem Lett Date: 2015-08-31 Impact factor: 4.345

3. Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.

Authors: Alicia Regueiro-Ren; Zheng Liu; Yan Chen; Ny Sin; Sing-Yuen Sit; Jacob J Swidorski; Jie Chen; Brian L Venables; Juliang Zhu; Beata Nowicka-Sans; Tricia Protack; Zeyu Lin; Brian Terry; Himadri Samanta; Sharon Zhang; Zhufang Li; Brett R Beno; Xiaohua S Huang; Sandhya Rahematpura; Dawn D Parker; Roy Haskell; Susan Jenkins; Kenneth S Santone; Mark I Cockett; Mark Krystal; Nicholas A Meanwell; Umesh Hanumegowda; Ira B Dicker
Journal: ACS Med Chem Lett Date: 2016-04-22 Impact factor: 4.345

4. Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.

Authors: Ebere Sonoiki; Christian Nsanzabana; Jennifer Legac; Kirthana M V Sindhe; Joseph DeRisi; Philip J Rosenthal
Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191